recivit 400 micrograms, sublingual tablets
ethypharm - fentanyl - sublingual tablet - 400 microgram(s) - phenylpiperidine derivatives; fentanyl
recivit 533 micrograms, sublingual tablets
ethypharm - fentanyl - sublingual tablet - 533 microgram(s) - phenylpiperidine derivatives; fentanyl
recivit 800 micrograms, sublingual tablets
ethypharm - fentanyl - sublingual tablet - 800 microgram(s) - phenylpiperidine derivatives; fentanyl
buprenorphine and naloxone tablet
remedyrepack inc. - buprenorphine (unii: 40d3scr4gz) (buprenorphine - unii:40d3scr4gz), naloxone (unii: 36b82amq7n) (naloxone - unii:36b82amq7n) - buprenorphine and naloxone sublingual tablets are indicated for the maintenance treatment of opioid dependence. buprenorphine and naloxone sublingual tablets should be used as part of a complete treatment plan that includes counseling and psychosocial support. buprenorphine and naloxone sublingual tablets are contraindicated in patients with a history of hypersensitivity to buprenorphine or naloxone as serious adverse reactions, including anaphylactic shock, have been reported [ see warnings and precautions ( 5.9 )]. risk summary the data on use of buprenorphine, one of the active ingredients in buprenorphine and naloxone sublingual tablets, in pregnancy, are limited; however, these data do not indicate an increased risk of major malformations specifically due to buprenorphine exposure. there are limited data from randomized clinical trials in women maintained on buprenorphine that were not designed appropriately to assess the risk of major malformations [see data
buprenorphine tablet
remedyrepack inc. - buprenorphine hydrochloride (unii: 56w8mw3en1) (buprenorphine - unii:40d3scr4gz) - buprenorphine 2 mg - buprenorphine sublingual tablet is indicated for the treatment of opioid dependence and is preferred for induction. buprenorphine sublingual tablet should be used as part of a complete treatment plan to include counseling and psychosocial support. buprenorphine sublingual tablet is contraindicated in patients with a history of hypersensitivity to buprenorphine, as serious adverse reactions, including anaphylactic shock, have been reported [see warnings and precautions (5.9)]. risk summary the data on use of buprenorphine, the active ingredient in buprenorphine sublingual tablets, in pregnancy, are limited; however, these data do not indicate an increased risk of major malformations specifically due to buprenorphine exposure. there are limited data from randomized clinical trials in women maintained on buprenorphine that were not designed appropriately to assess the risk of major malformations [see data]. observational studies have reported on congenital malformations among bup
buprenorphine tablet
remedyrepack inc. - buprenorphine hydrochloride (unii: 56w8mw3en1) (buprenorphine - unii:40d3scr4gz) - buprenorphine sublingual tablets are indicated for the treatment of opioid dependence and is preferred for induction. buprenorphine sublingual tablets should be used as part of a complete treatment plan to include counseling and psychosocial support. buprenorphine sublingual tablets are contraindicated in patients with a history of hypersensitivity to buprenorphine, as serious adverse reactions, including anaphylactic shock, have been reported [see warnings and precautions ( 5.9 ) ] . risk summary the data on use of buprenorphine, the active ingredient in buprenorphine sublingual tablets, in pregnancy, are limited; however, these data do not indicate an increased risk of major malformations specifically due to buprenorphine exposure. there are limited data from randomized clinical trials in women maintained on buprenorphine that were not designed appropriately to assess the risk of major malformations [see data] . observational studies have reported on congenital malformations amo
buprenorphine tablet
remedyrepack inc. - buprenorphine hydrochloride (unii: 56w8mw3en1) (buprenorphine - unii:40d3scr4gz) - buprenorphine sublingual tablets are indicated for the treatment of opioid dependence and are preferred for induction. buprenorphine sublingual tablets should be used as part of a complete treatment plan to include counseling and psychosocial support. buprenorphine sublingual tablets are contraindicated in patients with a history of hypersensitivity to buprenorphine, as serious adverse reactions, including anaphylactic shock, have been reported [see warnings and precautions (5.9)]. risk summary the data on use of buprenorphine, the active ingredient in buprenorphine sublingual tablets, in pregnancy, are limited; however, these data do not indicate an increased risk of major malformations specifically due to buprenorphine exposure. there are limited data from randomized clinical trials in women maintained on buprenorphine that were not designed appropriately to assess the risk of major malformations [see data] . observational st
yaz film-coated tablet
bayer (south east asia) pte ltd - (tablet core, product) drospirenone; (tablet core, product) ethinylestradiol betadex clathrate - tablet, film coated - 3.000 mg - (tablet core, product) drospirenone 3.000 mg; (tablet core, product) ethinylestradiol betadex clathrate 0.020 mg
pryzex olanzapine 10 mg tablet blister pack
arrotex pharmaceuticals pty ltd - olanzapine, quantity: 10 mg - tablet, uncoated - excipient ingredients: magnesium stearate; lactose; hyprolose; microcrystalline cellulose - pryzex tablets are indicated for ? treatment of schizophrenia and related psychoses. ? short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder. ? preventing recurrence of manic, mixed or depressive episodes in bipolar 1 disorder.
pryzex olanzapine 7.5 mg tablet blister pack
arrotex pharmaceuticals pty ltd - olanzapine, quantity: 7.5 mg - tablet, uncoated - excipient ingredients: hyprolose; lactose; microcrystalline cellulose; magnesium stearate - pryzex tablets are indicated for ? treatment of schizophrenia and related psychoses. ? short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder. ? preventing recurrence of manic, mixed or depressive episodes in bipolar 1 disorder.